Talha Badar
@TalhaBadarMD
Faculty @MayoCancerCare Alumni @MDAndersonNews Specialised in treating leukemia & myeloid disorder. Interest in ALL, TP53m MN & clonal hematopoiesis
🚨 Very excited to share my # IIT just prior to #ASH24 👉🏾 T-cell immune cluster analysis using CyTOF identifies unique subgroups... sciencedirect.com/science/articl… We found 2 unique immune clusters 👇🏽 among ND AML pts treated with VEN+HMA 1) immune depleted among responders 2) immune…
Indeed. Even a complex karyotype has prognostic value in TP53 mutated myeloid neoplasms. Thanks to @TalhaBadarMD Dr.Dan Arber @Anand_88_Patel @hematomenon and all the other iTiN collaborators for helping getting the word out. Cc: @UChicagoHemOnc @UChicagoPath
I am happy to have been a part of this study led by @PMadhaviMD and our mentor @gvencut1 @JClinPath_BMJ Read it at : jcp.bmj.com/content/early/… #PathTwitter #Match2026 #PathMatch26
American Journal of Hematology | Blood Research Journal | Wiley Online Library onlinelibrary.wiley.com/doi/10.1002/aj… PII trial of CPX-351 and Venetoclax, led by Dr. Tapan Kadia 👏👏 #leusm #AML CPX-351 dosed at daunorubicin 44 mg/m2 on days 1,3, and 5 and VEN 300 mg days 2–8) being chosen…
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia ashpublications.org/blood/article/… 70 cases of B-cell #ALL with lineage switch after immunotherapy (anti-CD19) to AML or mixed phenotypic leukemia. Dismal outcome with…
emjreviews.com/hematology/jou… Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias: highlights from #EHA2025 #EHA25
Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China ashpublications.org/blood/article-… The Ru-D regimen was well tolerated, resulting in OS rates of 85.7%, 67.9%, and 53.6% at 2 months, 6 months, and 2 years,…
✨ Honored and grateful to receive my 5-year service recognition from @MayoClinic Working at an institution that leads with values like compassion, integrity, innovation, and teamwork has been a deeply rewarding journey. I’m incredibly thankful for the colleagues, mentors, and…
Early View | Haematologica haematologica.org/newsletter/v1/… Phase 1 study( Blinatumomab post alloHCT for 2 cycles among patients in CR2 (children and young adults) #ALL #leusm Most of the G4 toxicities were haematological. Almost all pts received Blina pre-alloHCT
Top Heme-Onc Oncologists for Q2 2025, curated by @Larvol CLIN. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Hematology #Oncology #CancerResearch #CancerData #OncologyInsights | @FadiHaddad_MD | @VincentRK…
Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial - The Lancet Haematology thelancet.com/journals/lanha… 1. CR/CRi rate 77% in RR B-cell ALL…
Top 10 Heme-Onc Oncologists for June 2025, curated by @Larvol CLIN. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Hematology #Oncology #CancerResearch #CancerData #OncologyInsights | @FadiHaddad_MD |…
Karyotypic clonal fraction predicts adverse outcome in TP53-mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study jcp.bmj.com/content/early/… Happy to contribute to this paper led by Dr. Girish Venkataraman from University of Chicago, analyzing clonal…
Intermediate-Dose Cytarabine as Postinduction AML Therapy | NEJM Evidence evidence.nejm.org/doi/full/10.10… Deep dive on the recent paper published in @NEJMEvidence, randomized trial IDAC vs HDAC consolidation in AML (18-60 yrs). #leusm #AML Trial excluded CBF, Ph+ or MPN->AML Primary…
Intermediate-Dose Cytarabine as Postinduction AML Therapy | NEJM Evidence evidence.nejm.org/doi/full/10.10…
Happy to contribute to 2025 NCCN guidelines for patients with #ALL #endleukemia nccn.org/patients/guide…
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML | Journal of Clinical Oncology ascopubs.org/doi/full/10.12… Congratulations to Dr. Zeidner and BeatAML team. 1. Revumenib was given continuously, dose adjusted for CYP3A4i 2. Ven for 28…
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML | Journal of Clinical Oncology ascopubs.org/doi/full/10.12… 1.…
🚨 NEWS 🚨 @US_FDA grants fast track designation to nuvisertib, an oral, investigational, highly selective PIM1 kinase inhibitor, for the treatment of patients with intermediate or high-risk #myelofibrosis Read more: loom.ly/rhBmSLo #MPN #MPNsm #MedNews
25 Posts Not to Miss from EHA 2025 (@EHA_Hematology) @ASH_hematology | @NicoGagelmann | @knowyournodes | @AuclairDan | @TalhaBadarMD | @majorajay | @DrOlaLandgren | @VincentRK | @VivekSubbiah | @AnnaSureda5 | @Dr_AmerZeidan | @sanamloghavi | @SabrinaRanero…
Top Oncologists from @EHA_Hematology 2025. Explore the latest updates from #EHA2025: t.ly/6uoHY #LARVOL #Hematology #CancerResearch #Oncology #CancerData #OncologyInsights | @FadiHaddad_MD | @Eddie_Cliff | @calliecoombsmd | @TalhaBadarMD | @GuiperiniMD |…